Comparative Pharmacology
Head-to-head clinical analysis: OLAPARIB versus RUBRACA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OLAPARIB versus RUBRACA.
OLAPARIB vs RUBRACA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Poly (ADP-ribose) polymerase (PARP) inhibitor that blocks base excision repair, leading to accumulation of DNA double-strand breaks and cell death in tumors with homologous recombination repair deficiency.
Rucaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. It inhibits PARP enzymatic activity and traps PARP-DNA complexes, leading to DNA damage, apoptosis, and cell death in tumor cells with homologous recombination repair deficiencies (e.g., BRCA mutations).
300 mg orally twice daily, taken with or without food. For patients with BRCA-mutated advanced ovarian cancer after ≥3 prior lines of chemotherapy; or as maintenance therapy after platinum-based chemotherapy for recurrent ovarian cancer; or for HER2-negative metastatic breast cancer with germline BRCA mutation; or for metastatic pancreatic adenocarcinoma with germline BRCA mutation after first-line platinum-based chemotherapy; or for metastatic castration-resistant prostate cancer with HRR gene mutations.
600 mg orally twice daily, with or without food, total daily dose 1200 mg.
None Documented
None Documented
Clinical Note
moderateOlaparib + Digoxin
"Olaparib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateOlaparib + Digitoxin
"Olaparib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateOlaparib + Deslanoside
"Olaparib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateOlaparib + Acetyldigitoxin
"Olaparib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life ~11-12 hours; steady-state reached by day 3-5; supports BID dosing
The terminal elimination half-life (t1/2) is approximately 17 hours, supporting twice-daily dosing (600 mg twice daily) to maintain steady-state concentrations within the therapeutic window.
Fecal (84%), renal (6%) as unchanged drug; <1% in urine as metabolites
Approximately 44% of the administered dose is excreted in feces (with 38% as unchanged drug) and 28% in urine (with 7% as unchanged drug). The remainder is recovered as metabolites in feces and urine, with biliary excretion being a minor route.
Category C
Category C
PARP Inhibitor
PARP Inhibitor